Company Filing History:
Years Active: 2013
Title: Thomas Tradler: Innovator in Bradykinin B2 Receptor Modulation
Introduction
Thomas Tradler is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate the bradykinin B2 receptor. His innovative work has led to the filing of a patent that showcases his expertise and creativity in medicinal chemistry.
Latest Patents
Thomas Tradler holds a patent for "8-oxy-quinoline derivatives as bradykinin B2 receptor modulators." This invention relates to a compound of the formula (I) or a pharmacologically acceptable salt, solvate, or hydrate thereof. The compound features a 6-membered heteroaryl structure with 1 to 3 heteroatoms, which can be independently selected from nitrogen or oxygen. The other substituents are defined as specified in the claims of the patent. He has 1 patent to his name.
Career Highlights
Throughout his career, Thomas has worked with prominent companies in the pharmaceutical industry. He has been associated with Shire Orphan Therapies GmbH and Jerini AG, where he contributed to various innovative projects. His work in these organizations has helped advance therapeutic options for patients with specific medical needs.
Collaborations
Thomas Tradler has collaborated with several professionals in his field. Notable coworkers include Christoph Gibson and Karsten Schnatbaum, who have worked alongside him on various projects and research initiatives.
Conclusion
Thomas Tradler is a distinguished inventor whose work in bradykinin B2 receptor modulation has made a significant impact in pharmacology. His patent and collaborations reflect his dedication to advancing medical science and improving patient outcomes.